Apollo and J&J Face a High-Stakes Orthopedics Deal

Apollo and J&J Face a High-Stakes Orthopedics Deal Vardah Gill Tue, September 15, 2026 at 4:26 PM GMT+2 5 min read JNJ APO Apollo Global Management, Inc. (NYSE: APO ) is reportedly in talks to acquire Johnson & Johnson (NYSE: JNJ ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.

3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.

Apollo and J&J Face a High-Stakes Orthopedics Deal Apollo and J&J Could Both Unlock Value For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.

3 billion of 2025 revenue implies a price-to-sales multiple of about 2. 2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation. DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants.

Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1. 05 trillion of assets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.

For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits.

A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin. Story Continues Apollo Faces Deal Risks While J&J Could Give Up Future Upside For Apollo Global Management, Inc. (NYSE:APO), the principal risk is paying a full valuation for a business that J&J itself has been restructuring and that carries meaningful litigation exposure.

Reuters reported that DePuy Synthes faces lawsuits related to its hip-replacement devices, which creates uncertainty around potential liabilities and the ultimate economics of the transaction. The reported $20 billion valuation would also represent more than twice the unit's 2025 revenue, meaning Apollo would need meaningful margin improvement, growth, or both to generate an attractive private-equity return. There is also execution risk: orthopedics is a specialized medical-device business where product development, regulatory approvals, surgeon adoption, and litigation outcomes can materially affect returns.

Apollo's scale reduces financing constraints, but the deal would still expose its investors to the operating and legal risks of a single large healthcare asset rather than simply earning management fees on diversified assets. For Johnson & Johnson (NYSE:JNJ), the downside is that selling DePuy Synthes could sacrifice future upside from a business that still has considerable scale and technological opportunities. DePuy Synthes generated $9.

3 billion of revenue in 2025, and its recent investments in spine implants and robotic-surgery technology indicate that management has not treated the franchise as strategically stagnant. A sale also creates the possibility that J&J receives less long-term value than it could have generated through the planned spin-off, particularly if the standalone company benefits from greater strategic focus and eventually commands a stronger valuation. Moreover, J&J has already incurred substantial orthopedics restructuring costs, so selling immediately after that restructuring could limit the company's ability to capture the full benefit of those investments.

The choice between a sale and a tax-efficient public spin-off is therefore important: the former could provide certainty and liquidity, while the latter could preserve shareholder participation in any future recovery or margin expansion. Conclusion The potential transaction is more clearly positive for J&J strategically and more conditional for Apollo Global Management, Inc. (NYSE:APO) financially.

J&J has already decided to separate DePuy Synthes, so a potential transaction near $20 billion could turn an ongoing portfolio restructuring into a substantial monetization event and accelerate its move toward higher-growth, higher-margin businesses. For Apollo, DePuy Synthes offers a scaled healthcare platform with opportunities for operational improvement, but the roughly 2. 2x revenue valuation, litigation exposure, and execution requirements mean the investment case depends heavily on buying at the right price and expanding profitability.

Overall, J&J appears to have the cleaner near-term strategic catalyst, while Apollo's upside is greater if it can acquire the asset at an attractive valuation and successfully unlock the margin and growth potential that J&J identified when announcing the separation. While we acknowledge the potential of APO and JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: AstraZeneca's Oncology Engine Faces a Key Test After Camizestrant Miss and GSK Cuts 641 Jobs in Vaccine Manufacturing Restructuring This article is originally published at Insider Monkey .